• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form NT 10-Q filed by Scorpius Holdings Inc.

    5/15/25 5:24:59 PM ET
    $SCPX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $SCPX alert in real time by email
    NT 10-Q 1 scpx_12b25.htm NOTIFICATION OF LATE FILING NT10Q

     

     

    U.S. SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    FORM 12B-25

     

    NOTIFICATION OF LATE FILING

     

     

      SEC FILE NUMBER
    001-35994
       
      CUSIP NUMBER
    42237K 409

     

     

    (Check One): ☐ Form 10-K ¨ Form 20-F ¨ Form 11-K

    ☒ Form 10-Q ¨ Form 10-D ¨ Form N-CEN ¨ Form N-CSR

      

    For Period Ended: March 31, 2025

     

    ¨ Transition Report on Form 10-K

    ¨ Transition Report on Form 20-F

    ¨ Transition Report on Form 11-K

    ¨ Transition Report on Form 10-Q

     

    For the Transition Period Ended: N/A

     

    Read Instruction (on back page) Before Preparing Form. Please Print or Type.

    Nothing in this form shall be construed to imply that the Commission has verified any information contained herein.

     

     

    If the notification relates to a portion of the filing checked above, identify the Item(s) to which the notification relates:  N/A

     

        

    PART I. REGISTRANT INFORMATION.

     

    Scorpius Holdings, Inc.

    Full Name of Registrant

     

     

     

    Former Name if Applicable

     

    1305 E. Houston Street, Building 2

    Address of Principal Executive Office (Street and Number)

     

    San Antonio, TX 78205

    City, State and Zip Code

      

     

     
     

    PART II. RULES 12B-25 (b) AND (c)

     

    If the subject report could not be filed without unreasonable effort or expense and the registrant seeks relief pursuant to Rule 12b-25(b), the following should be completed. (Check box if appropriate.)

     

     

     

     

    ☐

    (a)  The reasons described in reasonable detail in Part III of this Form could not be eliminated without unreasonable effort or expense;

     

    (b)   The subject annual report, semi-annual report, transition report on Form 10-K, Form 20-F, 11-K, Form N-SAR or Form N-CSR, or portion thereof, will be filed on or before the fifteenth calendar day following the prescribed due date; or the subject quarterly report or transition report on Form 10-Q or subject distribution report on Form 10-D, or portion thereof, will be filed on or before the fifth calendar day following the prescribed due date; and

     

    (c)   The accountant's statement or other exhibit required by Rule 12b-25(c) has been attached if applicable.

     

     

    PART III. NARRATIVE

     

    The Company is unable to file its Quarterly Report on Form 10-Q for its quarter ended March 31, 2025. The compilation, dissemination and review of the financial information required to be presented in the Form 10-Q has imposed time constraints on the Company’s management that have rendered timely filing of the Form 10-Q impractical without undue hardship and expense to the Company.

     

     

    PART IV. OTHER INFORMATION

     

      (1) Name and telephone number of person to contact in regard to this notification:

     

    William Ostrander (919) 240-7133

     

      (2) Have all other periodic reports required under Section 13 or 15(d) of the Securities Exchange Act of 1934 or Section 30 of the Investment Company Act of 1940 during the preceding 12 months or for such shorter period that the Company was required to file such report(s) been filed? If the answer is no, identify report(s).

     

    x Yes                                        ¨   No

      

      (3) Is it anticipated that any significant change in results of operations from the corresponding period for the last fiscal year will be reflected by the earnings to be included in the subject report or portion thereof?

     

    x  Yes                                       ¨  No

     

    If so, attach an explanation of the anticipated change, both narratively and quantitatively, and, if appropriate, state the reasons why a reasonable estimate of the results cannot be made.

     

    The Company expects revenue for the quarter ended March 31, 2025 to be lower than the revenue for the quarter ended March 31, 2024 and net loss for the quarter ended March 31, 2025 to be higher than the net loss for the quarter ended March 31, 2024. The amounts are not yet determinable.

     

     

     
     

     

     

     

    Scorpius Holdings, Inc. has caused this notification to be signed on its behalf by the undersigned thereunto duly authorized.

     

      SCORPIUS HOLDINGS, INC.
         
         
    Dated:   May 15, 2025 By: /s/ William Ostrander
        William Ostrander
        Chief Financial Officer

     

     

     

     

     

    Get the next $SCPX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $SCPX

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $SCPX
    SEC Filings

    See more
    • Scorpius Holdings Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Unregistered Sales of Equity Securities, Financial Statements and Exhibits

      8-K - Scorpius Holdings, Inc. (0001476963) (Filer)

      6/3/25 4:30:27 PM ET
      $SCPX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Scorpius Holdings Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Unregistered Sales of Equity Securities, Financial Statements and Exhibits

      8-K - Scorpius Holdings, Inc. (0001476963) (Filer)

      5/20/25 5:07:29 PM ET
      $SCPX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form NT 10-Q filed by Scorpius Holdings Inc.

      NT 10-Q - Scorpius Holdings, Inc. (0001476963) (Filer)

      5/15/25 5:24:59 PM ET
      $SCPX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SCPX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more

    $SCPX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form SC 13G filed by Scorpius Holdings Inc.

      SC 13G - Scorpius Holdings, Inc. (0001476963) (Subject)

      9/26/24 4:05:52 PM ET
      $SCPX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Scorpius Holdings Inc.

      SC 13G - Scorpius Holdings, Inc. (0001476963) (Subject)

      9/6/24 4:01:41 PM ET
      $SCPX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D/A filed by Scorpius Holdings Inc. (Amendment)

      SC 13D/A - Scorpius Holdings, Inc. (0001476963) (Subject)

      5/21/24 5:25:39 PM ET
      $SCPX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 3 filed by new insider Thuan Tan Sze

      3 - Scorpius Holdings, Inc. (0001476963) (Issuer)

      3/12/25 4:07:02 PM ET
      $SCPX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Wolf Jeffrey Alan was granted 2,500,000 shares (SEC Form 4)

      4 - Scorpius Holdings, Inc. (0001476963) (Issuer)

      5/17/24 4:30:21 PM ET
      $SCPX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SCPX
    Leadership Updates

    Live Leadership Updates

    See more
    • Scorpius Holdings Announces Corporate Update Including Cost Optimization Initiatives, Strategic Corporate Developments, and Potential Opportunities for Expansion into Southeast Asia

      Operational Realignment Expected to Deliver Over $6 Million in Annual Cost Savings Company Exploring CDMO Expansion Opportunities in Southeast Asia San Antonio, TX , May 05, 2025 (GLOBE NEWSWIRE) -- Scorpius Holdings, Inc (OTC:SCPX) ("Scorpius" or "the Company"), an integrated contract development and manufacturing organization ("CDMO"), today provided a corporate update highlighting key strategic initiatives, including cost optimization measures expected to yield over $6 million in annualized savings and the Company's exploration of opportunities to expand operations into Southeast Asia through a potential biomanufacturing presence in Malaysia. Major Operational Cost Optimization Progr

      5/5/25 8:00:00 AM ET
      $SCPX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Scorpius Holdings Reports Third Quarter 2024 Results, Highlighting Strategic Partnerships, Cost Savings, and Progress Toward Profitability

      DURHAM, N.C., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Scorpius Holdings, Inc (NYSE American: SCPX) ("Scorpius" or "the Company"), an integrated contract development and manufacturing organization ("CDMO"), today provided a strategic, financial, and operational update for the third quarter ended September 30, 2024. Jeff Wolf, CEO of Scorpius Holdings, Inc., stated, "Scorpius continued to make strides in Q3, driven by key partnerships, disciplined financial management, and growth across our manufacturing and development services. We are proud to report a 142% year-over-year increase in revenue for the nine months ended September 30, 2024, reaching $5.2 million, which illustrates the demand fo

      11/14/24 4:15:00 PM ET
      $SCPX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Scorpius Holdings Selected to Join Medical CBRN Defense Consortium to Advance Medical Countermeasures Against Chemical, Biological, Radiological, and Nuclear Threats

      DURHAM, N.C., Oct. 02, 2024 (GLOBE NEWSWIRE) -- Scorpius Holdings, Inc (NYSE American: SCPX) ("Scorpius" or "the Company"), an integrated contract development and manufacturing organization ("CDMO"), today announced that it has been selected to join the Medical CBRN Defense Consortium (MCDC), a key organization advancing the development of medical countermeasures and related technologies to protect U.S. military personnel and civilians from chemical, biological, radiological, and nuclear (CBRN) threats. The MCDC, established in 2015 under the U.S. Department of Defense (DoD), serves as a collaborative framework for government, industry, and academia to partner on cutting-edge medical solu

      10/2/24 8:00:00 AM ET
      $SCPX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SCPX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Tivic Health Enters GMP Manufacturing Validation Agreement with Scorpius BioManufacturing in Preparation for FDA Submission

      Tivic Health® Systems, Inc. (NASDAQ:TIVC), a diversified therapeutics company, announced today it has entered a definitive agreement with Scorpius BioManufacturing to complete the GMP manufacturing validation of the lead candidate from its TLR5 program, Entolimod™, for treatment of Acute Radiation Syndrome, or ARS, in preparation for filing a Biological Licensing application, or BLA, with the U.S. Food & Drug Administration. Scorpius BioManufacturing, Inc. is an integrated contract development and manufacturing organization (CDMO) and subsidiary of Scorpius Holdings Inc. (OTC:SCPX), which will be the primary U.S. manufacturer for Entolimod™. Scorpius plans to utilize its scientific and tec

      5/14/25 8:30:00 AM ET
      $SCPX
      $TIVC
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
    • Scorpius Holdings Announces Corporate Update Including Cost Optimization Initiatives, Strategic Corporate Developments, and Potential Opportunities for Expansion into Southeast Asia

      Operational Realignment Expected to Deliver Over $6 Million in Annual Cost Savings Company Exploring CDMO Expansion Opportunities in Southeast Asia San Antonio, TX , May 05, 2025 (GLOBE NEWSWIRE) -- Scorpius Holdings, Inc (OTC:SCPX) ("Scorpius" or "the Company"), an integrated contract development and manufacturing organization ("CDMO"), today provided a corporate update highlighting key strategic initiatives, including cost optimization measures expected to yield over $6 million in annualized savings and the Company's exploration of opportunities to expand operations into Southeast Asia through a potential biomanufacturing presence in Malaysia. Major Operational Cost Optimization Progr

      5/5/25 8:00:00 AM ET
      $SCPX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Scorpius Holdings Provides 2024 Year-End Business Update; Implements Strategic Cost Reductions and Operational Streamlining

      SAN ANTONIO, April 30, 2025 (GLOBE NEWSWIRE) -- Scorpius Holdings, Inc (OTC: SCPX) ("Scorpius" or "the Company"), an integrated contract development and manufacturing organization ("CDMO"), today provided strategic, financial, and operational updates for the year ended December 31, 2024. Jeff Wolf, CEO of Scorpius Holdings, Inc., stated, "The current biotech funding environment has created real headwinds for many of our clients, particularly when it comes to advancing drug development and clinical trials. In response, we took decisive steps to streamline our operations, reduce our cost structure, and refocus on our core CDMO capabilities. While the delay in our Form 10-K filing was not id

      4/30/25 4:05:30 PM ET
      $SCPX
      Biotechnology: Pharmaceutical Preparations
      Health Care